2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

[1]  A. Burls,et al.  Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. , 2017, The Cochrane database of systematic reviews.

[2]  M. Boers,et al.  Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis , 2016, Rheumatology.

[3]  L. Mandl,et al.  Patients with Systemic Lupus Erythematosus Have Increased Risk of Short-term Adverse Events after Total Hip Arthroplasty , 2016, The Journal of Rheumatology.

[4]  G. Guyatt,et al.  A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. , 2016, Journal of clinical epidemiology.

[5]  T. Seyler,et al.  How Do Previous Solid Organ Transplant Recipients Fare After Primary Total Knee Arthroplasty? , 2016, The Journal of arthroplasty.

[6]  Anant Dixit,et al.  Thirty-day complications in rheumatoid patients following total knee arthroplasty , 2016, Clinical Rheumatology.

[7]  L. Mandl,et al.  Patients with Rheumatoid Arthritis have Similar Excellent Outcomes after Total Knee Replacement Compared with Patients with Osteoarthritis , 2016, The Journal of Rheumatology.

[8]  J. French,et al.  Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials , 2015, Arthritis Research & Therapy.

[9]  S. Goodman,et al.  Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. , 2015, Rheumatology.

[10]  M. Fornai,et al.  Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis , 2015, Drug Safety.

[11]  E. Keystone,et al.  Rituximab for Rheumatoid Arthritis , 2015, Rheumatology and Therapy.

[12]  P. Tugwell,et al.  Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis , 2015, The Lancet.

[13]  L. Mandl,et al.  Rheumatoid Arthritis Does Not Increase Risk of Short-term Adverse Events after Total Knee Arthroplasty: A Retrospective Case-control Study , 2015, The Journal of Rheumatology.

[14]  C. Salliot,et al.  SAT0141 Safety of Anti-TNFS in RA Patients in Real Life: Results from a Systematic Litterature Review and Meta-Analyses from Biologic Registers , 2015 .

[15]  J. Singh,et al.  Rheumatoid Arthritis is Associated With Higher Ninety‐Day Hospital Readmission Rates Compared to Osteoarthritis After Hip or Knee Arthroplasty: A Cohort Study , 2015, Arthritis care & research.

[16]  Sandhya Jinesh.  Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs , 2015, Inflammopharmacology.

[17]  H. Yamanaka,et al.  Postoperative complications in patients with rheumatoid arthritis using a biological agent – A systematic review and meta-analysis , 2015, Modern rheumatology.

[18]  Hyon K. Choi,et al.  The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. , 2014, The American journal of medicine.

[19]  H. Valdez,et al.  Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[20]  L. Mandl,et al.  Patients with Rheumatoid Arthritis Are More Likely to Have Pain and Poor Function After Total Hip Replacements than Patients with Osteoarthritis , 2014, The Journal of Rheumatology.

[21]  S. Bae,et al.  Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials , 2014, The Korean journal of internal medicine.

[22]  Peter Tugwell,et al.  Methotrexate for treating rheumatoid arthritis. , 2014, The Cochrane database of systematic reviews.

[23]  L. Mandl,et al.  US Trends in Rates of Arthroplasty for Inflammatory Arthritis Including Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritis , 2014, Arthritis & rheumatology.

[24]  S. Norton,et al.  Hand and Foot Surgery Rates in Rheumatoid Arthritis Have Declined From 1986 to 2011, but Large‐Joint Replacement Rates Remain Unchanged: Results From Two UK Inception Cohorts , 2014, Arthritis & rheumatology.

[25]  L. Mandl,et al.  Arthroplasty Rates Are Increased Among US Patients with Systemic Lupus Erythematosus: 1991–2005 , 2014, The Journal of Rheumatology.

[26]  R. Pontarolo,et al.  Efficacy and Safety of Biologic Therapies for Systemic Lupus Erythematosus Treatment: Systematic Review and Meta-Analysis , 2014, BioDrugs.

[27]  G. Hawker,et al.  Increased Risk of Complications Following Total Joint Arthroplasty in Patients With Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[28]  M. Petri,et al.  Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus , 2014, The Journal of Rheumatology.

[29]  C. Barnabe,et al.  Risk Factors for Infection Following Total Joint Arthroplasty in Rheumatoid Arthritis , 2013, The open rheumatology journal.

[30]  Kenneth K C Man,et al.  Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis , 2013, BMC Musculoskeletal Disorders.

[31]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[32]  Yang Zhang,et al.  Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population , 2013, European Journal of Orthopaedic Surgery & Traumatology.

[33]  Ta-Liang Chen,et al.  Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study , 2013, Annals of the rheumatic diseases.

[34]  G. Firestein,et al.  The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[35]  P. Tugwell,et al.  OP0071 Risk of Cancer, Serious Lung Infections and Death with Biologics: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTS) , 2013 .

[36]  F. Acurcio,et al.  Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis , 2013, Rheumatology International.

[37]  L. Mandl,et al.  Patterns and Associated Risk of Perioperative Use of Anti-Tumor Necrosis Factor in Patients with Rheumatoid Arthritis Undergoing Total Knee Replacement , 2013, The Journal of Rheumatology.

[38]  R. Pontarolo,et al.  Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis , 2012 .

[39]  G. Hawker,et al.  A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. , 2012, Arthritis and rheumatism.

[40]  M. Dougados,et al.  Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement , 2012, Annals of the rheumatic diseases.

[41]  J. Katz,et al.  The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. , 2012, Best practice & research. Clinical rheumatology.

[42]  Jiang‐hua Chen,et al.  Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis , 2012, Journal of Zhejiang University SCIENCE B.

[43]  Heather N. Watson,et al.  Economic burden of periprosthetic joint infection in the United States. , 2012, The Journal of arthroplasty.

[44]  J. Eckel-Passow,et al.  The Mayo Prosthetic Joint Infection Risk Score: Implication for Surgical Site Infection Reporting and Risk Stratification , 2012, Infection Control & Hospital Epidemiology.

[45]  C. Turkelson,et al.  American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. , 2012, The Journal of bone and joint surgery. American volume.

[46]  Yngve Falck-Ytter,et al.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[47]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[48]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[49]  S. Bae,et al.  The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials , 2011, Rheumatology International.

[50]  A. Troxel,et al.  The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. , 2011, Journal of the American Academy of Dermatology.

[51]  J. Pope,et al.  Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. , 2011, Arthritis and rheumatism.

[52]  R. Parker,et al.  Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. , 2011, Rheumatology.

[53]  J. Kremer,et al.  High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[54]  D. Furst,et al.  Rituximab for Rheumatoid Arthritis: A Meta-Analysis and Systematic Review , 2010 .

[55]  R. Pontarolo,et al.  Meta‐analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis , 2010, Pharmacotherapy.

[56]  D. Furst,et al.  Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis , 2010, The Korean journal of internal medicine.

[57]  E. Murray,et al.  Off-label use of rituximab in systemic lupus erythematosus: a systematic review , 2010, Clinical Rheumatology.

[58]  C. Hill,et al.  Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis , 2010, International journal of rheumatic diseases.

[59]  H. Calkins,et al.  2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. , 2009, Journal of the American College of Cardiology.

[60]  R. Pontarolo,et al.  A Systematic Review and Meta‐analysis of the Efficacy and Safety of Etanercept for Treating Rheumatoid Arthritis , 2009, Scandinavian journal of immunology.

[61]  M. Ramos-Casals,et al.  Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases , 2009, Lupus.

[62]  C. Combescure,et al.  Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials , 2009, Annals of the rheumatic diseases.

[63]  J. Ornato,et al.  [ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery]. , 2009, Masui. The Japanese journal of anesthesiology.

[64]  P. Marik,et al.  Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. , 2008, Archives of surgery.

[65]  W. Bamlet,et al.  Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[66]  M. Roman,et al.  Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. , 2008, The American journal of medicine.

[67]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[68]  Ismael R Ortega-Sanchez,et al.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[69]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[70]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[71]  D. Symmons,et al.  Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. , 2008, The Journal of rheumatology.

[72]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[73]  A. Alonso-Ruiz,et al.  Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety , 2008, BMC musculoskeletal disorders.

[74]  P. Tugwell,et al.  Generic quality-of-life assessment in rheumatoid arthritis. , 2007, The American journal of managed care.

[75]  J. Kaine.  Abatacept for the treatment of rheumatoid arthritis: A review. , 2007, Current therapeutic research, clinical and experimental.

[76]  F. Breedveld,et al.  Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response , 2007, Journal of clinical pharmacology.

[77]  V. Bykerk,et al.  Etanercept in the treatment of rheumatoid arthritis , 2007, Therapeutics and clinical risk management.

[78]  K. Lohr,et al.  The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. , 2006, The Journal of rheumatology.

[79]  Larry K. Pickering,et al.  General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[80]  P. Hannonen,et al.  Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[81]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[82]  Mimi Y. Kim,et al.  Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[83]  P. Peloso,et al.  Long term safety of etanercept in elderly subjects with rheumatic diseases , 2005, Annals of the rheumatic diseases.

[84]  Mimi Y. Kim,et al.  Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.

[85]  I. Nestorov.  Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.

[86]  D. Isenberg,et al.  How to monitor SLE in routine clinical practice , 2005, Annals of the rheumatic diseases.

[87]  H. Paulus,et al.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.

[88]  S. Ishii,et al.  Examination of the Risk of Continuous Leflunomide Treatment on the Incidence of Infectious Complications After Joint Arthroplasty in Patients With Rheumatoid Arthritis , 2003, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[89]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[90]  Benjamin Schwartz,et al.  General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[91]  D. Grennan,et al.  Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery , 2001, Annals of the rheumatic diseases.

[92]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[93]  Andrew W Kuhn,et al.  Post-operative medical and surgical complications after primary total joint arthroplasty in solid organ transplant recipients: a case series , 2016, International Orthopaedics.

[94]  Gerald Gartlehner,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[95]  R. Christensen,et al.  Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatoid Diseases: Network Meta-Analysis From a National Guideline Panel , 2013 .

[96]  A. Worsley,et al.  Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis , 2013 .

[97]  Z. Zou,et al.  The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials , 2009, European Journal of Clinical Pharmacology.

[98]  J. Singh,et al.  Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. , 2008, The American journal of managed care.